GILEAD SCIENCES INC (GILD)
US3755581036 - Common Stock
77.09 -0.56 (-0.72%)
After market: 77.2 +0.11 (+0.14%)
Fundamental Rating
Taking everything into account, GILD scores 4 out of 10 in our fundamental rating. GILD was compared to 629 industry peers in the Biotechnology industry. Both the profitability and the financial health of GILD get a neutral evaluation. Nothing too spectacular is happening here. GILD is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
The Piotroski-F score of GILD is 8.00. This is a very strong score and indicates great health and profitability for GILD.
GILD's Return On Equity of 26.59% is in line with the rest of the industry. The industry average Return On Equity is 22.69%.
GILD has a Return On Assets of 9.02%. This is below the industry average of 12.73%.
GILD's Profit Margin of 20.64% is worse than the rest of the industry. The industry average Profit Margin is 32.67%.
VS Industry
ROA (9.02%) VS Industry: 32% outperformed.
0.64
67.91
ROE (26.59%) VS Industry: 59% outperformed.
0.93
308.05
Profit Margin (20.64%) VS Industry: 37% outperformed.
1.94
682.87
Valuation
Valuation Rating
With a Price/Earnings Ratio of 11.82, the valuation of GILD can be described as very reasonable.
With a Forward Price/Earnings Ratio of 10.42, the valuation of GILD can be described as very reasonable.
GILD's Price/Earning Ratio is in line with the industry average which is at 13.96.
With a price book ratio of 4.58, GILD is valued correctly.
Compared to an average industry Enterprise Value to EBITDA ratio of 11.28, GILD is valued in line with its industry peers.
Compared to an average industry price book ratio of 1.82, GILD is valued more expensive than its industry peers. 80% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Earnings (11.82) VS Industry: 58% outperformed.
754.50
0.47
Price/Book (4.58) VS Industry: 20% outperformed.
255.75
0.09
Enterprise Value/ EBITDA (10.36) VS Industry: 58% outperformed.
360.74
0.19
Growth
Growth Rating
The EPS growth is accelerating: in the next 5 years the growth will be better than in the last years.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
Measured over the past 5 years, GILD shows a decrease in Earnings Per Share. The EPS has been decreasing by -3.84% on average per year.
The Earnings Per Share is expected to grow by 3.29% on average over the next 5 years.
Looking at the last year, GILD shows a decrease in Revenue. The Revenue has decreased by -1.56% in the last year.
The Revenue has been growing slightly by 0.88% on average over the past 5 years.
Based on estimates for the next 5 years, GILD will show a small growth in Revenue. The Revenue will grow by 2.53% on average per year.
GILD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.05%.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | -3.84% | 3.12% | -11.05% | -3.99% | 0.87% | 1.96% | 3.29% |
| Revenue | 0.88% | 6.71% | -1.56% | 0.78% | 1.49% | 1.94% | 2.53% |
Health
Health Rating
GILD is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of -1.15.
GILD has a very good Piotroski-F score of 8.00. This indicates a great health and profitability for GILD.
A Current Ratio of 1.28 indicates that GILD should not have too much problems paying its short term obligations.
GILD has a Quick Ratio of 1.13. This is a normal value and indicates that GILD is financially healthy and should not expect problems in meeting its short term obligations.
GILD has an Altman-Z score of 2.72. This is not the best score and indicates that GILD is in the grey zone with still only limited risk for bankruptcy at the moment.
When comparing the Current Ratio of GILD to the average industry Current Ratio of 5.40, GILD is less able to pay its short term obligations than its industry peers. 89% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 5.24, GILD is worse placed to pay its short term obligations than its industry peers. 90% of its industry peers have a better Quick Ratio.
GILD has one of the worst Debt to Equity ratios in its industry. 95% of its industry peers require less debt for financing their operations.
VS Industry
Debt/Equity (1.09) VS Industry: 5% outperformed.
22.69
0.00
Quick Ratio (1.13) VS Industry: 10% outperformed.
0.02
87.97
Current Ratio (1.28) VS Industry: 11% outperformed.
0.04
87.97
Altman-Z (2.72) VS Industry: 70% outperformed.
-289.03
312.45
Dividend
Dividend Rating
GILD's Dividend Yield is a higher than the S&P500 average which is at 2.72.
On average, the dividend of GILD grows each year by 7.27%, which is quite nice.
GILD has been paying a dividend for over 5 years, so it has already some track record.
GILD has a Yearly Dividend Yield of 3.86%. Purely for dividend investing, there may be better candidates out there.
With a Dividend Yield of 3.86, GILD pays less dividend than the industry average, which is at 3.92. 100% of the companies listed in the same industry pay a better dividend than GILD!
GILD's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
66.86% of the earnings are spent on dividend by GILD. This is not a sustainable payout ratio.
VS Industry
Dividend Yield (3.86%) VS Industry: 0% outperformed.
3.86
4.27
GILEAD SCIENCES INC
NASDAQ:GILD (5/26/2023, 7:27:38 PM)
After market: 77.2 +0.11 (+0.14%)77.09
-0.56 (-0.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-27 2023-04-27/amc
Earnings (Next)07-31 2023-07-31/amc
Inst Owners81.86%
Inst Owner Change-1.77%
Ins Owners0.06%
Ins Owner Change45.77%
Market Cap96.16B
Analysts71.89
Price Target92.99 (20.63%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.86% |
Dividend Growth(5Y)7.27%
DP66.86%
Div Incr Years7
Div Non Decr Years7
Ex-Date06-14 2023-06-14 (0.75)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.52%
Min EPS beat(2)-12.56%
Max EPS beat(2)9.52%
EPS beat(4)3
Avg EPS beat(4)7.44%
Min EPS beat(4)-12.56%
Max EPS beat(4)30.66%
Revenue beat(2)1
Avg Revenue beat(2)3.7%
Min Revenue beat(2)-1.67%
Max Revenue beat(2)9.08%
Revenue beat(4)3
Avg Revenue beat(4)6.26%
Min Revenue beat(4)-1.67%
Max Revenue beat(4)12.74%
PT rev (1m)0.86%
PT rev (3m)2.29%
EPS NQ rev (1m)-0.27%
EPS NQ rev (3m)-0.31%
EPS NY rev (1m)0%
EPS NY rev (3m)1.38%
Revenue NQ rev (1m)0.33%
Revenue NQ rev (3m)2.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.82 | ||
| Fwd PE | 10.42 | ||
| P/S | 3.56 | ||
| P/FCF | 11.47 | ||
| P/OCF | 10.71 | ||
| P/B | 4.58 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.36 |
EPS(TTM)6.52
EY8.46%
EPS(NY)7.4
Fwd EY9.6%
FCF(TTM)6.72
FCFY8.72%
OCF(TTM)7.2
OCFY9.33%
SpS21.68
BVpS16.83
TBVpS-12.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.02% | ||
| ROE | 26.59% | ||
| ROIC | 13.21% | ||
| ROICexc | 14.91% | ||
| ROICexgc | 76.93% | ||
| OM | 32.68% | ||
| PM | 20.64% | ||
| GM | 79.17% |
ROICexgc(3y)74.76%
ROICexcg growth 3Y37.37%
ROICexcg growth 5Y-0.15%
ROICexc(3y)12.82%
ROICexc growth 3Y10.76%
ROICexc growth 5Y-12.7%
OM growth 3Y22.78%
OM growth 5Y-7.78%
PM growth 3Y-11.14%
PM growth 5Y-1.03%
GM growth 3Y0.04%
GM growth 5Y-0.98%
F-Score8
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 3.01 | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 26.6% | ||
| Profit Quality | 150.19% | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.13 | ||
| Altman-Z | 2.72 |
F-Score8
WACC7.91%
ROIC/WACC9.73
Cap/Depr(3y)35.59%
Cap/Depr(5y)46.04%
Profit Quality(3y)2155.83%
Profit Quality(5y)1351.8%
Growth
EPS 1Y-11.05%
EPS 3Y3.12%
EPS 5Y-3.84%
EPS growth Q2Q-35.38%
EPS Next Y-3.99%
EPS Next 2Y0.87%
EPS Next 3Y1.96%
EPS Next 5Y3.29%
Revenue growth 1Y-1.56%
Revenue growth 3Y6.71%
Revenue growth 5Y0.88%
Revenue growth Q2Q-3.61%
Revenue Next Year0.78%
Revenue Next 2Y1.49%
Revenue Next 3Y1.94%
Revenue Next 5Y2.53%
EBIT growth 1Y-10.95%
EBIT growth 3Y31.03%
EBIT growth 5Y-6.97%
EBIT Next Year6.02%
EBIT Next 3Y4.89%
EBIT Next 5Y7.3%
FCF growth 1Y-3.6%
FCF growth 3Y0.1%
FCF growth 5Y-5.9%
OCF growth 1Y-3.93%
OCF growth 3Y-0.26%
OCF growth 5Y-5.28%
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA